Annovis to Attend AD/PD™ 2025 with Extensive Scientific Program

Rhea-AI Summary

Annovis Bio (NYSE: ANVS) announced its participation in the AD/PD™ 2025 conference taking place April 1-5 in Vienna, where they will present comprehensive data from their latest clinical trials.

The company will deliver two key presentations: one focusing on buntanetap's improvements in cognition and motor functions in Phase 3 Parkinson's disease study, and another examining the drug's advantages for APOE4 carriers in Phase 2/3 Alzheimer's disease trials. Additionally, CEO Maria Maccecchini will participate in a forum discussion about novel approaches to biomarkers, imaging, and therapy development.

The presentations schedule includes:

• April 1, 2:45 PM CET: Buntanetap's impact on early Parkinson's patients
• April 2, 9:40 AM CET: APOE4 and buntanetap in Alzheimer's patients
• April 4, 4:20 PM CET: Forum on novel approaches in PD, LBD and MSA pathologies

News Market Reaction

+6.49%

1 alert

+6.49% News Effect

On the day this news was published, ANVS gained 6.49%, reflecting a notable positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

MALVERN, Pa., March 25, 2025 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE: ANVS) ("Annovis"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced its participation in the AD/PD™ 2025 taking place April 1-5 in Vienna.

"We are at a pivotal moment in our company’s journey as we have entered the late clinical stages for both Alzheimer’s and Parkinson’s. It is incredibly rewarding to see our work bring us here, once again supporting that our drug is efficacious and safe across both indications,” commented Maria Maccecchini, Ph.D., Founder and CEO of Annovis. “At this meeting, we will present comprehensive data from our latest Phase 3 PD and Phase 2/3 AD studies. For Parkinson’s, we will take a deeper look into the cognitive response, while for Alzheimer’s, we will dive into the advantages of buntanetap for APOE4 carriers, addressing a pressing challenge in existing AD therapies."

Annovis will give two presentations and participate in a forum discussion:

Presentation: BUNTANETAP IMPROVES EARLY PARKINSON’S PATIENTS’ COGNITION AND MOTOR FUNCTIONS IN A PHASE 3 STUDY

• Date: April 1
• Time: 2:45 – 3:00 pm CET
• Presenter: Maria Maccecchini, Ph.D., Founder and CEO
  

Presentation: APOE4 AND BUNTANETAP IN PHASE II/III ALZHEIMER’S PATIENTS

• Date: April 2
• Time: 9:40 – 9:55 am CET
• Presenter: Cheng Fang, Ph.D., SVP, Research and Development
  

Forum: NOVEL APPROACHES TO ACCELERATE DEVELOPMENT OF BIOMARKERS, IMAGING, AND THERAPY OF ALPHA-SYNUCLEIN, LRKK2, AND GBA PATHOLOGIES LINKED TO PD, LBD AND MSA

• Date: April 4
• Time: 4:20 – 5:20 pm CET
• Participant: Maria Maccecchini, Ph.D., Founder and CEO
  

The AD/PD™ 2025 conference brings together the brightest minds in the field in order to share the latest breakthroughs in treatment, translational R&D, early diagnosis, drug development and clinical trials in AD, PD, and other related neurological disorders.

About Annovis
Headquartered in Malvern, Pennsylvania, Annovis is dedicated to addressing neurodegeneration in diseases such as AD and PD. The Company is committed to developing innovative therapies that improve patient outcomes and quality of life. For more information, visit www.annovisbio.com and follow us on LinkedIn, YouTube, and X.

Investor Alerts
Interested investors and shareholders are encouraged to sign up for press releases and industry updates by registering for email alerts at https://www.annovisbio.com/email-alerts.

Forward-Looking Statements
This press release contains forward-looking statements under the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended. Actual results may differ due to various risks and uncertainties, including those outlined in the Company’s SEC filings under “Risk Factors” in its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company undertakes no obligation to update forward-looking statements except as required by law.

Contact Information:
Annovis Bio Inc.
101 Lindenwood Drive
Suite 225
Malvern, PA 19355
www.annovisbio.com

Investor Contact:
Alexander Morin, Ph.D.
Director, Strategic Communications
Annovis Bio
ir@annovisbio.com

FAQ

What clinical trial results will Annovis Bio (ANVS) present at AD/PD 2025?

Annovis Bio will present data from their Phase 3 Parkinson's disease study showing buntanetap's effects on cognition and motor functions, and Phase 2/3 Alzheimer's trial results focusing on benefits for APOE4 carriers.

When and where will Annovis Bio (ANVS) present at AD/PD 2025?

Annovis Bio will present at AD/PD 2025 in Vienna from April 1-5, with specific presentations on April 1 at 2:45 PM, April 2 at 9:40 AM, and a forum discussion on April 4 at 4:20 PM CET.

What is buntanetap's potential impact on APOE4 carriers with Alzheimer's?

Annovis Bio will present data about buntanetap's advantages for APOE4 carriers in their Phase 2/3 Alzheimer's trial, addressing a significant challenge in existing AD therapies.

How is Annovis Bio (ANVS) advancing their Parkinson's disease treatment?

Annovis Bio has reached late clinical stages in Parkinson's disease treatment, with Phase 3 study results showing improvements in patients' cognition and motor functions using buntanetap.

What neurodegenerative conditions is Annovis Bio (ANVS) targeting with buntanetap?

Annovis Bio is developing buntanetap for both Alzheimer's disease and Parkinson's disease, with late-stage clinical trials showing efficacy and safety across both indications.